KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Halozyme Therapeutics (HALO) over the last 15 years, with Q3 2025 value amounting to -$307000.0.

  • Halozyme Therapeutics' Gains from Investment Securities fell 10713.95% to -$307000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $78.4 million, marking a year-over-year increase of 13644.28%. This contributed to the annual value of $80.6 million for FY2024, which is 15386.7% up from last year.
  • Per Halozyme Therapeutics' latest filing, its Gains from Investment Securities stood at -$307000.0 for Q3 2025, which was down 10713.95% from -$2.6 million recorded in Q2 2025.
  • Over the past 5 years, Halozyme Therapeutics' Gains from Investment Securities peaked at $78.0 million during Q4 2024, and registered a low of -$2.9 million during Q2 2024.
  • Over the past 5 years, Halozyme Therapeutics' median Gains from Investment Securities value was $525000.0 (recorded in 2022), while the average stood at $8.3 million.
  • Per our database at Business Quant, Halozyme Therapeutics' Gains from Investment Securities soared by 274083.19% in 2022 and then crashed by 2644545.45% in 2024.
  • Over the past 5 years, Halozyme Therapeutics' Gains from Investment Securities (Quarter) stood at $1.2 million in 2021, then surged by 2740.83% to $33.5 million in 2022, then decreased by 8.73% to $30.5 million in 2023, then skyrocketed by 155.35% to $78.0 million in 2024, then crashed by 100.39% to -$307000.0 in 2025.
  • Its last three reported values are -$307000.0 in Q3 2025, -$2.6 million for Q2 2025, and $3.3 million during Q1 2025.